When we assessed the BCR-ABL downstream signaling pathways, we observed that RXRA agonist in combination with IM resulted in decreased p-CRKL, p-STAT5, and p-AKT along with activation of the apoptotic cascade in CML cell lines and primary cells. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.